

Luis M Branco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1514484/publications.pdf>

Version: 2024-02-01

34
papers

1,554
citations

394421

19
h-index

477307

29
g-index

34
all docs

34
docs citations

34
times ranked

1823
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus. <i>Cell</i> , 2015, 162, 738-750.	28.9	230
2	Lassa Fever in Post-Conflict Sierra Leone. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2748.	3.0	172
3	Structural basis for antibody-mediated neutralization of Lassa virus. <i>Science</i> , 2017, 356, 923-928.	12.6	170
4	Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. <i>Nature Communications</i> , 2016, 7, 11544.	12.8	148
5	Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. <i>Nature Medicine</i> , 2017, 23, 1146-1149.	30.7	95
6	Detection of Lassa Virus, Mali. <i>Emerging Infectious Diseases</i> , 2010, 16, 1123-1126.	4.3	89
7	Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. <i>Virology Journal</i> , 2011, 8, 478.	3.4	69
8	Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. <i>Antiviral Research</i> , 2016, 133, 218-222.	4.1	57
9	Analysis of CD8 ⁺ T cell response during the 2013-2016 Ebola epidemic in West Africa. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E7578-E7586.	7.1	55
10	Geographic Distribution and Genetic Characterization of Lassa Virus in Sub-Saharan Mali. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2582.	3.0	49
11	Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: Case Report. <i>Virology Journal</i> , 2011, 8, 314.	3.4	41
12	Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. <i>Scientific Reports</i> , 2018, 8, 5939.	3.3	39
13	Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization. <i>Cell</i> , 2019, 178, 1004-1015.e14.	28.9	39
14	An Outbreak of Ebola Virus Disease in the Lassa Fever Zone. <i>Journal of Infectious Diseases</i> , 2016, 214, S110-S121.	4.0	34
15	Antibody therapy for Lassa fever. <i>Current Opinion in Virology</i> , 2019, 37, 97-104.	5.4	28
16	Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali. <i>Emerging Infectious Diseases</i> , 2016, 22, 657-663.	4.3	26
17	Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail. <i>Viruses</i> , 2021, 13, 1202.	3.3	26
18	Bacterial-based systems for expression and purification of recombinant Lassa virus proteins of immunological relevance. <i>Virology Journal</i> , 2008, 5, 74.	3.4	24

#	ARTICLE	IF	CITATIONS
19	Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans. <i>Viruses</i> , 2021, 13, 2325.	3.3	24
20	High crossreactivity of human T cell responses between Lassa virus lineages. <i>PLoS Pathogens</i> , 2020, 16, e1008352.	4.7	22
21	Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies. <i>Cell Reports</i> , 2022, 39, 110841.	6.4	17
22	Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages. <i>Scientific Reports</i> , 2020, 10, 16030.	3.3	15
23	Identification of Common CD8 ⁺ T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone. <i>Journal of Virology</i> , 2020, 94, .	3.4	15
24	Annual Incidence of Lassa Virus Infection in Southern Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 96, 16-0821.	1.4	14
25	Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak. <i>Scientific Reports</i> , 2020, 10, 8724.	3.3	14
26	Ebola-Specific CD8 ⁺ and CD4 ⁺ T-Cell Responses in Sierra Leonean Ebola Virus Survivors With or Without Post-Ebola Sequelae. <i>Journal of Infectious Diseases</i> , 2020, 222, 1488-1497.	4.0	13
27	Neutralizing Antibodies against Lassa Virus Lineage I. <i>MBio</i> , 2022, 13, .	4.1	12
28	Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012–2019. <i>Microorganisms</i> , 2021, 9, 586.	3.6	10
29	Host Proteins Identified in Extracellular Viral Particles as Targets for Broad-Spectrum Antiviral Inhibitors. <i>Journal of Proteome Research</i> , 2018, 18, 7-17.	3.7	7
30	From Kenema to Our Krios: Medical Defense Against Lassa Virus and Emerging Infectious Disease. <i>Microscopy and Microanalysis</i> , 2020, 26, 568-568.	0.4	0
31	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0
32	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0
33	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0
34	High crossreactivity of human T cell responses between Lassa virus lineages. , 2020, 16, e1008352.		0